Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

DOI PDF 2 Citations
  • Sung Won Choi
    Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
  • Thomas Braun
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI;
  • Israel Henig
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;
  • Erin Gatza
    Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
  • John Magenau
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;
  • Brian Parkin
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;
  • Attaphol Pawarode
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;
  • Mary Riwes
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;
  • Greg Yanik
    Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
  • Charles A. Dinarello
    Department of Medicine, University of Colorado, Aurora, CO; and
  • Pavan Reddy
    Department of Medicine, Michigan Medicine, Ann Arbor, MI;

Description

<jats:title>Key Points</jats:title> <jats:p>Grade 2 to 4 acute GVHD in URD HCT patients who received vorinostat and tacrolimus/methotrexate after myeloablative conditioning was 22%. HDAC inhibition with vorinostat shows potential efficacy for GVHD prevention and should be investigated in a randomized phase 3 trial.</jats:p>

Journal

  • Blood

    Blood 130 (15), 1760-1767, 2017-10-12

    American Society of Hematology

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top